Penta-O-galloyl-β-D-glucose and its effects on breast cancer cells
Author Information
Author(s): Chai Yubo, Lee Hyo-Jeong, Shaik Ahmad Ali, Nkhata Katai, Xing Chengguo, Zhang Jinhui, Jeong Soo-Jin, Kim Sung-Hoon, Lü Junxuan
Primary Institution: The Hormel Institute, University of Minnesota
Hypothesis
The novel targeting actions of PGG are applicable to breast cancer cells, especially those lacking proven drugable targets.
Conclusion
PGG shows potential as a drug candidate for breast cancer, particularly for triple-negative types, by inducing cell cycle arrests and apoptosis.
Supporting Evidence
- PGG treatment led to over 60% inhibition of MDA-MB231 xenograft growth.
- PGG induced S-phase arrest in both MCF-7 and MDA-MB231 cells.
- PGG decreased cyclin D1 expression in both cell lines.
- PGG treatment did not induce P21Cip1 or P27Kip1 expression.
Takeaway
A natural compound called PGG can help stop breast cancer cells from growing and can even kill them, especially in hard-to-treat cases.
Methodology
The study used mono-layer cell culture models and in vivo xenograft models to assess the effects of PGG on breast cancer cells.
Potential Biases
Potential biases may arise from the lack of critical controls in previous studies referenced.
Limitations
The study did not include time-matched controls for some comparisons.
Participant Demographics
The study involved female athymic nude mice for in vivo experiments.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website